• English
    • Ελληνικά
    • Deutsch
    • français
    • italiano
    • español
  • English 
    • English
    • Ελληνικά
    • Deutsch
    • français
    • italiano
    • español
  • Login
View Item 
  •   University of Thessaly Institutional Repository
  • Επιστημονικές Δημοσιεύσεις Μελών ΠΘ (ΕΔΠΘ)
  • Δημοσιεύσεις σε περιοδικά, συνέδρια, κεφάλαια βιβλίων κλπ.
  • View Item
  •   University of Thessaly Institutional Repository
  • Επιστημονικές Δημοσιεύσεις Μελών ΠΘ (ΕΔΠΘ)
  • Δημοσιεύσεις σε περιοδικά, συνέδρια, κεφάλαια βιβλίων κλπ.
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.
All of DSpace
  • Communities & Collections
  • By Issue Date
  • Authors
  • Titles
  • Subjects

Dabigatran: The anticoagulant we have long expected?

Thumbnail
Author
Tagarakis, G. I.; Karangelis, D.; Daskalopoulos, M. E.; Tsilimingas, N. B.
Date
2010
DOI
10.2174/157489010793351926
Keyword
Anticoagulant &
Dabigatran
Prevention
acetylsalicylic acid
amiodarone
clarithromycin
cyclosporin
dabigatran etexilate
enoxaparin
esomeprazole
garlic extract
ginger extract
ibuprofen
lansoprazole
macrolide
metronidazole
mifepristone
nonsteroid antiinflammatory agent
omeprazole
pantoprazole
pradax
protamine sulfate
quinidine
rifampicin
ritonavir
unclassified drug
verapamil
vitamin K group
warfarin
abdominal discomfort
abdominal pain
anticoagulation
article
bleeding
clinical trial
diarrhea
drug indication
drug safety
dyspepsia
fatigue
human
nausea
osteoporosis
patent
pharmacodynamics
priority journal
skin disease
vein thrombosis
venous thromboembolism
vomiting
Administration, Oral
Anticoagulants
Benzimidazoles
beta-Alanine
Humans
Metadata display
Abstract
Many researchers have until now united their efforts in the endeavor to discover new anticoagulants, which would be simpler to use and safer to administer, so that patients would avoid both thromboembolic events as well as life threatening episodes of bleeding. One of these agents, that is hereby presented along with patents, is dabigatran, which promises much for the future, despite the fact that time and the awaited results of ongoing trials will be necessary for its establishment as a first-line anticoagulant. More specifically, based on the major trials of RELY and RECOVER, we could state that dabigatran has presented satisfactory outcomes in terms of bleeding and prevention of venous thromboembolism. © 2010 Bentham Science Publishers Ltd.
URI
http://hdl.handle.net/11615/33536
Collections
  • Δημοσιεύσεις σε περιοδικά, συνέδρια, κεφάλαια βιβλίων κλπ. [9735]
Η δικτυακή πύλη της Ευρωπαϊκής Ένωσης
Ψηφιακή Ελλάδα
ΕΣΠΑ 2007-2013
 

 

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

My Account

LoginRegister (MyDspace)
Help Contact
DepositionAboutHelpContact Us
Choose LanguageAll of DSpace
EnglishΕλληνικά
Η δικτυακή πύλη της Ευρωπαϊκής Ένωσης
Ψηφιακή Ελλάδα
ΕΣΠΑ 2007-2013